On November 16, Moderna, Inc. recorded an Overnight Decline of 3.04%, trading at $216.59 per share, with turnover of $5.0614 million.
The move followed continued cautious market reaction to the company’s recent analyst day update, while options flow turned more clearly bearish.
Management had outlined about $9 billion of year-end liquidity, projected cash costs of about $4 billion in 2027, extended its $1.5 billion Ares credit facility to 2031, and raised its revenue growth outlook to 15% to 25%, while indicating infectious disease vaccine profitability could improve. Even so, recent market focus remained on investment intensity and execution pace. Supporting that cautious tone, the latest options activity showed a $5.385 million bear put spread and a $1.0095 million bear call spread, pointing to institutional positioning for further medium-term weakness.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments